| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Not fully defined; 5-Methoxy-5-oxopentanoic acid is an endogenous metabolite with potential bioactivities. It has been reported to induce erasure of genomic imprints with a potency of 1258.9 nM, act as an agonist of the Thyroid Stimulating Hormone Receptor with a potency of 5011.9 nM, and activate intracellular cAMP concentrations in parental HEK 293 cells. It also inhibits the growth of various human tumor cell lines at a GI₅0 of 100,000.0 nM. However, the primary molecular target is not well-defined. As an endogenous metabolite, it may be involved in various metabolic pathways and may serve as a substrate or intermediate in enzymatic reactions.
|
|---|---|
| ln Vitro |
5-Methoxy-5-oxopentanoic acid has been shown to have anti-inflammatory and antioxidant activity in vitro. It has been reported to induce erasure of genomic imprints with a potency of 1258.9 nM, act as an agonist of the Thyroid Stimulating Hormone Receptor with a potency of 5011.9 nM, and activate intracellular cAMP concentrations in parental HEK 293 cells. It also inhibits the growth of various human tumor cell lines at a GI₅0 of 100,000.0 nM. These bioactivities suggest potential roles in cell signaling and metabolic regulation. The compound is also a metabolite of dibasic esters (DBEs) in nasal and olfactory mucosae. It is an endogenously produced metabolite.
|
| ln Vivo |
5-Methoxy-5-oxopentanoic acid is an endogenous metabolite present in the body. As a metabolite of dibasic esters (DBEs) in nasal respiratory and olfactory mucosae, it is involved in the metabolism of these compounds. Its anti-inflammatory and antioxidant activities suggest potential in vivo effects in reducing inflammation and oxidative stress. However, detailed in vivo pharmacological studies are limited. The compound may be involved in various metabolic pathways and may serve as a biomarker for certain metabolic states. It is not used as a therapeutic agent but rather as an analytical reference standard for biochemical and metabolic research.
|
| Enzyme Assay |
For analytical quantification by LC-MS/MS, prepare a stock solution of 5-Methoxy-5-oxopentanoic acid in DMSO or methanol at 1-10 mg/mL. Add the compound to biological samples (plasma, urine, tissue homogenates) as an external standard or use an appropriate internal standard (e.g., a deuterated analog). Protein precipitation with acetonitrile or methanol is followed by centrifugation. Separate on a C18 reverse-phase column using a mobile phase of 0.1% formic acid in water and acetonitrile. Detect by negative ion electrospray ionization (ESI-) and multiple reaction monitoring (MRM). Quantify against a calibration curve prepared from the reference standard. This protocol is used for metabolite quantification and metabolic profiling studies.
|
| Cell Assay |
For cell-based studies of anti-inflammatory or antioxidant activity, culture cells (e.g., macrophages, HEK293 cells) in appropriate medium. Treat cells with 5-Methoxy-5-oxopentanoic acid at concentrations ranging from 0.1-1000 uM for 24-72 hours. Measure cell viability by MTT or CCK-8 assay. For anti-inflammatory activity, pre-treat cells with the compound for 1-2 hours, then stimulate with LPS (1 ug/mL) for 6-24 hours. Measure inflammatory cytokines (TNF-alpha, IL-6, IL-1beta) in culture supernatants by ELISA and nitric oxide (NO) by Griess reagent. For antioxidant activity, measure intracellular ROS by DCFH-DA. The compound has been shown to have anti-inflammatory and antioxidant activity. It also activates intracellular cAMP concentrations in parental HEK 293 cells, which can be measured by cAMP ELISA.
|
| Animal Protocol |
For in vivo pharmacokinetic or metabolic studies, administer 5-Methoxy-5-oxopentanoic acid or its parent compounds (e.g., dibasic esters) to animals (e.g., rats, mice) by oral gavage or intravenous injection. Collect blood, urine, and tissues at multiple time points (0, 0.5, 1, 2, 4, 6, 8, 12, 24 h). Add the compound (as an external standard) or an appropriate internal standard to samples. Precipitate proteins with acetonitrile, centrifuge, and analyze by LC-MS/MS as described above. Quantify the compound to assess its absorption, distribution, metabolism, and excretion. The compound is a metabolite of dibasic esters (DBEs) by nasal respiratory and olfactory mucosae.
|
| ADME/Pharmacokinetics |
5-Methoxy-5-oxopentanoic acid: Molecular formula C₆H10O4. Molecular weight: 146.14 g/mol. Appearance: Colorless to light yellow liquid. Density: ~1.169 g/cm3. Purity: ≥98%; reported up to 99.3%. Solubility: DMSO 100 mg/mL (684.28 mM). Storage: Powder at -20degC for 3 years, 4degC for 2 years; In solvent at -80degC for 6 months, at -20degC for 1 month. Shipping: Room temperature (stable for a few days during ordinary shipping). The compound is also known as mono-Methyl glutarate, METHYL HYDROGEN GLUTARATE.
|
| Toxicity/Toxicokinetics |
5-Methoxy-5-oxopentanoic acid has low toxicity as an endogenous metabolite at physiological levels. At high concentrations, it may cause mild skin and eye irritation. Standard laboratory safety precautions should be followed when handling the pure compound: wear appropriate personal protective equipment (lab coat, gloves, safety glasses), avoid inhalation of liquid or vapor and contact with skin/eyes, wash hands thoroughly after handling. Not for human therapeutic use. Always consult the Safety Data Sheet (SDS) for detailed safety information. It is supplied as an analytical reference standard for research use only.
|
| Additional Infomation |
Monomethyl glutarate is a dicarboxylic acid monoester of monomethyl glutarate. It is a metabolic product found in human urine and is functionally related to glutaric acid.
5-Methoxy-5-oxopentanoic acid is an endogenous metabolite with molecular formula C₆H10O4 and molecular weight 146.14 g/mol. It is a metabolite of dibasic esters (DBEs) by nasal respiratory and olfactory mucosae. The compound has demonstrated anti-inflammatory and antioxidant activity and is classified as an endogenous metabolite. It has been reported to induce erasure of genomic imprints (potency 1258.9 nM), act as an agonist of the Thyroid Stimulating Hormone Receptor (potency 5011.9 nM), and activate intracellular cAMP concentrations in HEK 293 cells. It also inhibits the growth of various human tumor cell lines at a GI₅0 of 100,000.0 nM. For research use only, not for human use. |
| Molecular Formula |
C6H10O4
|
|---|---|
| Molecular Weight |
146.14
|
| Exact Mass |
146.057
|
| CAS # |
1501-27-5
|
| PubChem CID |
73917
|
| Appearance |
Colorless to light yellow liquid
|
| Density |
1.169
|
| Boiling Point |
150-151 ºC
|
| Melting Point |
150 - 151 °C
|
| Flash Point |
110 ºC
|
| Vapour Pressure |
0.0±1.2 mmHg at 25°C
|
| Index of Refraction |
1.438
|
| LogP |
0.2
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
10
|
| Complexity |
130
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O(C([H])([H])[H])C(C([H])([H])C([H])([H])C([H])([H])C(=O)O[H])=O
|
| InChi Key |
IBMRTYCHDPMBFN-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C6H10O4/c1-10-6(9)4-2-3-5(7)8/h2-4H2,1H3,(H,7,8)
|
| Chemical Name |
5-methoxy-5-oxopentanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (684.28 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (17.11 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (17.11 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (17.11 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.8428 mL | 34.2138 mL | 68.4275 mL | |
| 5 mM | 1.3686 mL | 6.8428 mL | 13.6855 mL | |
| 10 mM | 0.6843 mL | 3.4214 mL | 6.8428 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
